None listed
Conditions
Interventions
Rifaximin Type of group
One 200 mg tablet of rifaximin, plus one identical placebo capsule, will be administered three times a day for 3 days.
Group name:Placebo Type of group
Two equal capsules will be administered three times a day for 3 days.
Sponsors
SANKYO PHARMA DEVELOPMENT,
Eligibility
Inclusion criteria
Inclusion criteria: Subjects of male or female sex 18 years of age or older. A minimum of three stool stools not formed within 24 hours prior to randomization. Provide a sample of fecal matter prior to the study that is verified as not formed. Experience at least one of the signs or symptoms of enteric infection.
Exclusion criteria
Exclusion criteria: Acute diarrhea for more than 72 hours. Moderate or severe dehydration. Active, uncontrolled and / or clinically significant diseases or disorders of the heart, lung, kidney, gastrointestinal tract
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:Interval that begins with the first dose of the clinical trial material and ends with the last evacuation of unformed stools. Measure:Duration of diarrhea after the start of study therapy, which will be measured using the time to the last stool stool not formed for rifaximin, compared to a placebo. Timepoints:for 5 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:The number of stool stools not formed evacuated by time interval Measure:The number of stool stools not formed evacuated by time interval Timepoints:for 5 days | — |
Countries
Argentina, Guatemala, India, Mexico, Peru, Singapore
Outcome results
None listed